Cabazitaxel

Phase 2/3Completed

1 views this week 0 watching💤 Quiet

Interest: 38/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Transitional Cell Carcinoma

Conditions

Transitional Cell Carcinoma

Trial Timeline

Jan 1, 2013 → Nov 1, 2017

NCT ID

NCT01668459

About Cabazitaxel

Cabazitaxel is a phase 2/3 stage product being developed by Sanofi for Transitional Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01668459. Target conditions include Transitional Cell Carcinoma.

What happened to similar drugs?

0 of 9 similar drugs in Transitional Cell Carcinoma were approved

Approved (0) Terminated (3) Active (6)

🔄Vepugratinib + EV + PembrolizumabEli LillyPhase 3

❌AtezolizumabRochePhase 3

🔄vinflunine and best supportive careBristol Myers SquibbPhase 3

🔄padeliporfin VTPICON plc.Phase 3

🔄UGN-101 instillationsUroGen PharmaPhase 3

🔄NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

❌NDV-01 (sustained-release gemcitabine-docetaxel)Relmada TherapeuticsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01981668	Phase 1	Withdrawn	—	—	Prostatic Neoplasms
NCT03050866	Phase 2	UNKNOWN	Feb 21, 2017	Aug 19, 2022	Circulating Tumor Cell
NCT02621190	Phase 2	Withdrawn	Feb 1, 2016	Jun 1, 2019	Prostatic Neoplasms
NCT02512458	Phase 2	Completed	Oct 29, 2015	Dec 27, 2019	Bone Metastatic Prostate Cancer
NCT02166658	Phase 2	Terminated	Aug 1, 2015	Jan 18, 2018	Breast Cancer
NCT02478502	Phase 2	Terminated	Jun 1, 2015	Dec 31, 2022	Testicular Cancer
NCT03114254	Phase 2	Completed	Dec 5, 2014	Nov 16, 2016	Penile Neoplasm
NCT01913652	Phase 2	Completed	Oct 1, 2014	Dec 1, 2020	Dedifferentiated Liposarcoma
NCT02115165	Phase 2	Completed	Jul 27, 2014	Apr 24, 2023	Non-seminomatous Germ-cell Tumors
NCT01952223	Phase 3	Active	Dec 1, 2013	Jul 1, 2041	Adenocarcinoma of Prostate
NCT01913067	Phase 2	Withdrawn	Sep 1, 2013	Sep 1, 2016	Brain Metastasis
NCT01740570	Phase 1/2	Withdrawn	Apr 1, 2013	—	Brain Cancer
NCT01747239	Phase 2	Terminated	Jan 1, 2013	Jul 1, 2014	Ovarian Cancer
NCT01668459	Phase 2/3	Completed	Jan 1, 2013	Nov 1, 2017	Transitional Cell Carcinoma
NCT01757171	Phase 2	Completed	Dec 1, 2012	Jun 1, 2017	Gastric Adenocarcinoma
NCT01693549	Phase 2	Completed	Sep 1, 2012	Jul 20, 2017	Breast Cancer
NCT01254279	Phase 3	Completed	Dec 1, 2010	Dec 1, 2014	Prostate Cancer Metastatic

Competing Products

20 competing products in Transitional Cell Carcinoma

See all competitors

Product	Company	Stage	Hype Score
Enfortumab vedotin	Astellas Pharma	Phase 2	35
enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine	Astellas Pharma	Phase 1/2	36
Pemetrexed + Gemcitabine + Platinol	Eli Lilly	Phase 1/2	32
Vepugratinib + EV + Pembrolizumab	Eli Lilly	Phase 3	47
durvalumab and tremelimumab	AstraZeneca	Phase 2	35
Docetaxel + vandetanib + Placebo	AstraZeneca	Phase 2	35
MK-3475 and BCG	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	31
Everolimus + Everolimus + Paclitaxel	Novartis	Phase 2	27
Buparlisib	Novartis	Phase 2	35
BEZ235	Novartis	Phase 2	27
Atezolizumab	Roche	Phase 3	32
Gemcitabine + Cisplatin + Sunitinib Malate	Pfizer	Phase 2	27
Nivolumab/Ipilimumab	Bristol Myers Squibb	Phase 2	31
vinflunine and best supportive care	Bristol Myers Squibb	Phase 3	40
vinflunine	Bristol Myers Squibb	Phase 2	35
Dasatinib	Bristol Myers Squibb	Pre-clinical	26
Docetaxel + Oxaliplatin	Sanofi	Phase 2	35
Rogaratinib (BAY1163877) + Chemotherapy	Bayer	Phase 2/3	35
CG0070 Adenovirus Vector	CG Oncology	Phase 2/3	27